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Adenosine Deaminase Deficiency – 
More Than Just an immunodeficiency
Kathryn V. Whitmore and Hubert B. Gaspar*
Molecular and Cellular Immunology Section, UCL Institute of Child Health, University College London, London, UK
Adenosine deaminase (ADA) deficiency is best known as a form of severe combined 
immunodeficiency (SCID) that results from mutations in the gene encoding ADA. 
Affected patients present with clinical and immunological manifestations typical of a 
SCID. Therapies are currently available that can target these immunological disturbances 
and treated patients show varying degrees of clinical improvement. However, there 
is now a growing body of evidence that deficiency of ADA has significant impact on 
non-immunological organ systems. This review will outline the impact of ADA deficiency 
on various organ systems, starting with the well-understood immunological abnormali-
ties. We will discuss possible pathogenic mechanisms and also highlight ways in which 
current treatments could be improved. In doing so, we aim to present ADA deficiency as 
more than an immunodeficiency and suggest that it should be recognized as a systemic 
metabolic disorder that affects multiple organ systems. Only by fully understanding ADA 
deficiency and its manifestations in all organ systems can we aim to deliver therapies that 
will correct all the clinical consequences.
Keywords: adenosine deaminase, immunodeficiency, SCiD, neurological abnormalities, enzyme replacement 
therapy, hematopoietic stem cell transplantation, gene therapy
iNTRODUCTiON
what is the Role of Adenosine Deaminase in the Purinergic 
Signaling Pathway?
Adenosine deaminase (ADA) is a ubiquitously expressed metabolic enzyme that plays an integral 
role in numerous cellular processes. It is expressed both intracellularly and, in certain cell types, is 
also complexed with CD26 on the cell surface. Enzymatically, ADA functions as part of the purine 
salvage pathway, catalyzing the irreversible deamination of adenosine and deoxyadenosine as shown 
in Figure 1 (1).
Deficient and impaired ADA activity results in the accumulation of metabolic substrates of which 
adenosine, deoxyadenosine, and dATP are of particular importance due to their profound effects 
on cellular function (2). Lymphocyte maturation and function is particularly affected and, hence, 
deficiency of ADA leads to a severe combined immunodeficiency (SCID) (1). It should be noted that 
there is an extracellular form of ADA2 that is coded for by the CECR1 gene (3). Mutations in ADA2 
can lead to polyarteritis nodosa and other vasculopathies, and indeed some patients with immuno-
deficiency have been identified (4–6). However, for the purpose of this review, we will discuss only 
ADA1 encoded for by the ADA gene, since this is the enzyme that is implicated in ADA-SCID, and 
we will refer to it throughout as ADA.
FiGURe 1 | The purine salvage pathway is an integral metabolic 
pathway, responsible for the regulation and availability of purines. 
ADA catalyzes the deamination of adenosine and deoxyadenosine, forming 
inosine and deoxyinosine (respectively), which can then undergo further 
downstream processing. Alternatively, adenosine and deoxyadenosine may 
be released to activate downstream pathways.
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what is ADA-SCiD?
Adenosine deaminase deficiency is caused by mutations in the 
ADA gene, and there is a correlation between the severity of the 
mutation, the level of ADA activity, and the level of metabolic 
disturbance (7). ADA deficiency is one of the most prevalent 
forms of SCID and accounts for 15–20% of all cases (1, 8). It is 
inherited in an autosomal recessive manner and has an overall 
incidence of ~1:200,000 live births (7). Diagnosis occurs most 
commonly during infancy and more than 85% of diagnoses occur 
during the first 6 months of life (7, 9). Initial presentations include 
recurrent and opportunistic fungal, viral and bacterial infections, 
lymphopenia, and a failure to thrive (10). Without therapeutic 
intervention, ADA deficiency has a fatal course due to severe and 
overwhelming infections and most patients will die within the 
first year of life (1, 7). Late onset forms are also known, although 
the manifestations appear to be milder.
what Are the Treatments for ADA-SCiD?
Various treatment options are currently available for ADA 
deficiency, as shown in Figure 2, including enzyme replacement 
therapy (ERT), hematopoietic stem cell transplantation (HSCT, 
sometimes referred to as bone marrow transplantation), and 
more recently gene therapy (GT) (10).
Enzyme replacement therapy, HSCT, and GT are all viable 
treatment options, tailored to individual patient circumstance 
and treatment availability. Varying levels of immune reconstitu-
tion can be achieved by each, and the treatments generally cor-
rect the immunological impairment, albeit to different extents 
(12, 14). HSCT and GT are curative treatment options and tend 
to be favored, while ERT offers a more immediate treatment 
option for patients upon initial diagnoses and often acts as a 
stabilizing measure, while alternative and definitive options are 
identified (12, 13).
While the focus largely remains on the immunological 
compartment, a multi-organ pathology can be expected in a 
metabolic disorder, such as ADA deficiency, because of the ubiq-
uitous nature of ADA expression. Therefore, in this review, we 
will outline the impact of ADA on various organ systems, start-
ing with the immunological abnormalities. We will also discuss 
possible pathogenic mechanisms and thereby highlight areas 
of improvement for current treatments. In doing so, we aim to 
present ADA deficiency as more than an immunodeficiency – it 
should be recognized as a systemic metabolic disorder that results 
in multiple organ pathologies.
ADA iN THe iMMUNe SYSTeM
The metabolic deficiency of ADA principally affects the immune 
system, and is characterized by severe lymphopenia (affecting 
T cells, B cells, and NK cells) and impaired cellular and humoral 
immunity (1, 15). Patients, therefore, present early in life with 
recurrent infections and a failure to thrive. Current evidence sug-
gests that the immune deficiency is a direct consequence of ADA 
deficiency, through the accumulation of metabolic substrates and 
their subsequent downstream effects.
Much research has been conducted to elucidate the mecha-
nism behind the different elements of the immunodeficiency. 
This section of the review will focus on, in particular, the effect 
of ADA deficiency on the development of the immune system, 
the functioning of the T- and B-cell compartments, and the effect 
on autoimmunity, highlighting important pieces of evidence and 
discussing proposed mechanisms of pathophysiology.
evidence for Abnormal Thymocyte 
Development and Function
Under normal metabolic circumstances, extremely high levels of 
ADA enzyme are found within the thymus and, therefore, ADA 
deficiency will likely lead to an especially devastating effect in 
this organ (16). In the mouse model, analysis of 3-week-old 
ADA-deficient mice found that the organs of the immune system 
(thymus, lymph nodes) were decreased in size and contained 
fewer cells in comparison to littermate controls (17). The 
observations made within this Apasov led study are indicative 
of lymphopenia, which appeared to be progressive in the mice, 
with more severe lymphopenia being seen at a 3-week analysis 
compared to earlier time points. Furthermore, although the 
immune system organs appeared smaller, no changes in levels of 
apoptosis were detected in the peripheral lymph organs (spleen, 
lymph nodes), but increased levels of apoptosis were identified 
in ADA-deficient thymi – the cortical and medullary regions 
being particularly affected. Evidence of abnormal thymocyte 
distribution in ADA-deficient mice (specifically a decrease in 
FiGURe 2 | Potential treatment options for ADA deficiency include enzyme replacement therapy (eRT), hematopoietic stem cell transplantation 
(HSCT), and gene therapy (GT). There are varying benefits and potential problems for each available treatment and patients require individual assessment to 
decide on the appropriate course of action. This table has been created using information from (1, 10–13).
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the number of CD4+ and CD8+ double-positive thymocytes) 
demonstrates defective thymocyte development (7, 17). This is 
concurrent with evidence from patients, where severe thymus 
atrophy and a decrease in thymic dendritic cells are reported 
(18). However, it is largely unknown which stage of thymocyte 
development and differentiation is arrested by ADA deficiency. 
A body of evidence exists to suggest that more differentiated 
thymocyte populations (double positive, single positive) are sig-
nificantly reduced in number, most likely due to a developmental 
or differentiation block at an earlier stage (19). Double-negative 
thymocytes represent a population early on in the maturation 
process and are subdivided into four stages (DNI–DNIV). Some 
evidence suggests that the aforementioned block occurs at the 
DNIII stage, at a time between the T-cell receptor (TCR)-β 
and TCR-α gene rearrangements (20). However, contradictory 
evidence has since suggested that the block in differentiation 
might not occur at a discrete stage, but is instead due to 
inhibited proliferation of more mature thymocytes (19). The 
induction of apoptosis continues to be implicated in the defec-
tive thymocyte development (19, 20). Therefore, while there is 
sufficient evidence to suggest abnormal thymocyte development 
and differentiation, the exact stage of block remains unknown 
and research is ongoing.
evidence for Abnormal T-Cell Function
Patients with ADA deficiency show a striking T-cell depletion 
and this is also replicated, albeit to a lesser extent, in the murine 
model (21). Despite this T-cell lymphopenia, ADA-deficient 
mice appeared to have a normal distribution of peripheral 
T  cells,  although the expression of cell surface markers was 
altered in comparison to control mice, for example, in both 
CD4+ and CD8+ ADA-deficient T cells, CD44 and CD69 
expression was increased while CD62L expression was decreased 
(17). The murine model of ADA deficiency additionally shows 
defective TCR activation in  vivo, which is suggested to be 
adenosine mediated (17). T cells from ADA-deficient patients 
have also proven to be defective in transducing signals through 
the TCR; however, in patients, it is suggested that it is not 
adenosine, but 2′deoxyadenosine that exacerbates the defective 
TCR  signaling (18, 22).
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evidence for Abnormal B-Cell 
Development and Function
The immunodeficiency associated with ADA deficiency also 
affects B cells, and patients exhibit severe B-cell lymphopenia 
and hypogammaglobulinemia. In murine studies led by Aldrich, 
initial stages of B-cell development occurring in the bone 
marrow were not shown to be impaired in ADA deficiency 
(23). Results of this study, therefore, implicate either differ-
entiation within the peripheral lymphoid organs or signaling 
via the B-cell receptor in the observed B-cell phenotype. The 
ADA-deficient mice exhibited smaller spleens with reduced 
cellularity and altered B-cell distribution among marginal, 
follicular, and newly formed splenic zones (17, 23). Further 
splenic alterations observed include fewer and smaller germinal 
centers with abnormal architecture (23). Therefore, from this 
study, it seems likely that while ADA deficiency does not impair 
primary B-cell development in the bone marrow, the B-cell 
defect is due to abnormal differentiation in peripheral lymphoid 
organs possibly due to an intrinsic B-cell defect or due to the 
lack of T-cell help. Formation of the germinal center is severely 
impacted in ADA deficiency, which is likely to affect antigen 
dependent development of B cells and subsequent generation of 
B-cell memory. In fact, B lymphocytes in ADA-deficient mice 
appeared to have reduced proliferative ability, with accumula-
tion of IgM antibodies and concomitant low levels of IgG (23). 
Furthermore, these B lymphocytes showed defects in activation, 
with a high tendency to undergo B-cell receptor-mediated 
apoptosis, potentially caused by the increased levels of dATP 
detected in the spleen.
Similar results have been shown in untreated ADA-SCID 
patients, whereby, despite peripheral lymphopenia, only a partial 
block in B-cell development is demonstrated within the bone 
marrow (24). On the contrary, untreated ADA-SCID patients 
displayed a twofold decrease in the number of B cells found 
in later developmental stages, suggesting that the B-cell defect 
affects more mature B cells, one hypothesis being that B cells pos-
sibly require different levels of ADA during differentiation (24). 
Furthermore, the importance of ADA to normal B-cell function 
has been demonstrated by the reduced proliferation of B cells 
from ADA-SCID patients in vitro, despite these patients receiving 
ERT, and also by the reduction in B-cell activating factor recep-
tor (BAFF-R) in these patients (24, 25). The BAFF-R is expressed 
on peripheral B cells and it is integral not only in maintaining 
peripheral B-cell homeostasis but also in determining the num-
ber of mature B cells (24, 25).
Therefore, cumulative defects in the typical B-cell response 
contribute to the B-cell lymphopenia observed in ADA defi-
ciency (23). Existing evidence suggests that ADA deficiency 
also affects the B-cell compartment in terms of repertoire 
diversity (26). Eliciting a response to a broad range of antigens 
is integral to the functioning of the immune system, and V(D)J 
recombination contributes to the diverse B-cell repertoire (27). 
It has been demonstrated that accumulating levels of dATP, 
secondary to ADA deficiency, may affect V(D)J recombination, 
in terms of the frequency and the nature of specific nucleotide 
insertions (26).
evidence for Autoimmunity
Autoimmunity is a condition commonly associated with some 
primary immune deficiencies (PID) (28). ADA-SCID represents 
a PID in which extensive immune dysregulation may disrupt 
integral adaptive and innate immune pathways that normally 
lead to the development of tolerance (1). This is especially found 
in delayed onset ADA phenotypes where there is some evidence 
of T/B-cell development, which is likely to be abnormal, and also 
in patients who are reconstituting after PEG-ADA treatment. 
Furthermore, complete immune reconstitution is not achieved 
by the available treatments, and this may increase the likelihood 
of developing autoimmunity (1). The causes of autoimmunity are 
not well established but may well relate to dysregulated T- and 
B-cell development and the lack of appropriate regulation.
Toxic effect Caused by 2′Deoxyadenosine
2′deoxyadenosine is currently favored as one of the causal factors 
in the development of immunodeficiency associated with ADA-
SCID (16). 2′deoxyadenosine is a component of DNA, and large 
amounts are generated from DNA degradation (1). Apoptosis 
is abundant in the thymus, thus providing a large source of 
DNA for degradation (1, 29). It is likely that the accumulation 
and uncontrolled elevation of 2′deoxyadenosine, which cannot 
be metabolized in ADA-deficient patients, exerts lymphotoxic 
effects either at the nucleoside level or after conversion to dATP 
by intracellular thymic deoxynucleoside kinase (1, 29).
Acting at the nucleoside level, 2′deoxyadenosine irreversibly 
inactivates S-adenosyl-l-homocysteine (SAH) hydrolase (16). 
Inhibition of SAH hydrolase prevents hydrolysis of SAH, and the 
accumulated SAH inhibits transmethylation reactions, which are 
necessary for lymphocyte activation (1, 7, 10, 30). This, therefore, 
severely impacts the immune system.
An additional metabolic pathway affected by ADA deficiency 
is the increased phosphorylation of 2′deoxyadenosine to form 
dATP (16). As levels of circulating 2′deoxyadenosine increase, 
cellular uptake also increases, and 2′deoxyadenosine undergoes 
intracellular phosphorylation (1). The accumulation of dATP 
in erythrocytes and lymphocytes is significant – dATP is an 
inhibitor of ribonucleotide reductase that is necessary for deoxy-
nucleotide synthesis, and its inhibition depletes the intracellular 
deoxynucleotide pool (1, 7, 16). Hence, inhibition of ribonucleo-
tide reductase impairs DNA synthesis, replication, and repair; 
processes that are integral to lymphocyte expansion following 
antigenic challenge (1, 7, 16).
There are also reports that both deoxyadenosine and dATP 
can have an effect on various apoptotic signaling cascades. It has 
been reported that deoxyadenosine interacts with p53 apoptotic 
pathway (22). Studies also suggest that dATP is involved in the 
loss of cytochrome c from the mitochondria and dATP has been 
implicated in activation of apoptotic protease-activating factor 1 
(APAF-1) (7, 31, 32).
Toxic effect Caused by Adenosine
Adenosine deaminase deficiency leads to accumulation of both 
2′deoxyadenosine and adenosine. An alternate hypothesis is 
that elevated concentrations of adenosine can affect the immune 
FiGURe 3 | This figure shows the cell membrane with the adenosine 
receptors embedded into the phospholipid bilayer. Adenosine receptors 
are G-protein-coupled receptors made up of seven transmembrane domains. 
There are four subtypes of adenosine receptor: A1, A2A, A2B, and A3. The 
A1 and A3 adenosine receptors are coupled to Gαi, which causes a 
decrease in cAMP downstream of receptor activation. Conversely, A2A and 
A2B are both coupled to Gαs, which causes an increase in cAMP.
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system via activation of its cognate G-protein-coupled receptors 
(GPCR) found on the plasma membrane of target cells (see 
Figure 3) (22).
Adenosine, therefore, functions as an extracellular signaling 
molecule: under normal physiological conditions, it plays a role 
in fine-tuning the immune response (1). However, this balanced 
regulation might be disrupted when adenosine concentrations 
are elevated, as in ADA deficiency. For example, activation of the 
A2A adenosine receptor by adenosine mediates immunosuppres-
sive actions: cAMP generated downstream of receptor activation 
acts via a negative feedback loop to inhibit and trigger “off ” 
signaling pathways in activated immune cells (33). It has been 
suggested that the defective TCR-dependent activation, charac-
teristic in ADA deficiency, may be exacerbated by this adenosine 
receptor-mediated immunosuppression (1). Investigating studies 
show that increased cAMP, produced by A2A receptor activa-
tion, interferes with signaling events that occur once the TCR 
have been activated and, therefore, may also inhibit downstream 
effector functions. The ability of exogenous adenosine to reduce 
TCR-triggered activation has also been shown both in vivo and 
in vitro in CD4+ and CD8+ T cells (22).
The proposed mechanisms for the observed immunological 
abnormalities are summarized in Figure 4.
ADA iN THe BRAiN
Adenosine is ubiquitously expressed, in both the peripheral and 
central nervous systems (CNS). In the CNS, adenosine functions 
as a neuromodulator, influencing synaptic transmission and 
integrating various signaling networks within the brain (34). As 
in the periphery, there are four subtypes of adenosine receptor in 
the CNS; the A1 and A2A receptor subtypes predominate, while 
A3 and A4 are much less prevalent (see Figure 5) (34).
There have been significant advances in the treatment of ADA-
SCID, resulting in improved levels of immune reconstitution and, 
therefore, prolonged survival rates (15). As patients are now sur-
viving for longer, an increasing number of non-immunological 
manifestations are being identified with cognitive, behavioral, 
and neurological abnormalities being among the most important 
of these non-immunological manifestations.
evidence for Cognitive and Behavioral 
Abnormalities
When assessing cognitive ability, SCID patients generally achieve 
below average IQ scores – however, the level of function is shown 
to be dependent upon the specific type of SCID (37, 38). Patients 
with ADA-SCID consistently achieve IQ scores that are not 
only below the population average but also below that of other 
SCID groups (37, 38). Furthermore, ADA-SCID patients exhibit 
hyperactivity, attention deficits, aggressive behavior, and social 
problems, scoring abnormally in all of these areas of behavior 
(37). An inverse relationship has been observed between cogni-
tive ability and behavioral difficulties: ADA-deficient patients 
with lower IQ scores showed increased incidence of emotional 
and behavioral difficulties (38).
While this evidence seems to implicate ADA deficiency, it 
has previously been postulated that the observed cognitive and 
behavioral abnormalities, also present in other forms of SCID, 
might in fact be a treatment side effect (39). In particular, HSCT is 
suspected to cause such neurological abnormalities as a side effect 
(40, 41). However, studies have shown that cognitive and behav-
ioral abnormalities are more frequently observed in ADA-SCID 
patients than in other SCID groups, despite both cohorts receiv-
ing HSCT as treatments (37, 38). Although there are a number of 
possible causative variables, a body of evidence now suggests that 
IQ score, and therefore cognitive ability, is perhaps not greatly 
affected by factors, such as age at transplantation, conditioning 
regime, and time spent in hospital, and it is, therefore, unlikely 
that the cognitive abnormalities are caused by the treatment itself 
(37, 38, 40, 42). Rather, a significant inverse correlation between 
dATP levels at diagnosis and total IQ has been demonstrated 
(37). Therefore, it seems likely that deficiency of ADA and the 
underlying metabolic disturbances are implicated in the estab-
lishment and/or development of the observed behavioral and 
cognitive abnormalities. Interestingly, ADA is a polymorphic 
enzyme where one of the alloenzymes (ADA1*2) demonstrates 
a 35% reduction in enzymatic activity (43). The polymorphism 
involves an Asp to Asn amino acid substitution at position 8 of 
the mature protein, and data from a particular study suggests 
that it is more likely to find this rare low-activity polymorphism 
[ADA-Asn8 (ADA1*2)] in children with mild mental retardation 
of unknown causes, when compared to both healthy controls and 
children with moderate to severe mental retardation of known 
causes (43). Therefore, this extends the theory that deficiency 
of ADA may be implicated in the cognitive abilities mentioned 
above, since similar observations are also made in patients with a 
low-activity ADA polymorphism.
evidence for Auditory Abnormalities
A spectrum of auditory abnormalities have been reported in 
patients with ADA deficiency, in particular, bilateral sensori-
neural deafness has been investigated as a non-immunological 
manifestation of ADA deficiency (44, 45). One of the earliest 
reports of bilateral sensorineural deafness in ADA deficiency 
describes two siblings who achieved normal immune reconstitu-
tion after being successfully treated with HSCT (45). However, 
severe deafness and mild hearing loss was exhibited in these 
FiGURe 4 | ADA deficiency leads to an accumulation of adenosine (A) and deoxyadenosine (B) – different mechanisms are proposed for the 
increased concentration of each metabolic substrate. (A) An increase in extracellular adenosine concentration leads to an increase in intracellular cyclic AMP 
(cAMP) caused by increased A2A receptor activation. cAMP is proposed to mediate lymphotoxic effects by disrupting TCR signaling and inhibiting the immune 
response to a stimulus. (B) Extracellular accumulation of 2′deoxyadenosine increases the intracellular concentration of 2′deoxyadenosine via diffusion down its 
concentration gradient. 2′deoxyadenosine inhibits SAH hydrolase and plays a role in apoptosis, by activating the p53 pathway. Alternatively, 2′deoxyadenosine can 
undergo conversion to dATP. dATP inhibits ribonucleotide reductase and also plays a role in apoptosis.
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patients at 1 year of age, with no identifiable genetic-, structural-, 
drug-, or infection-related cause. Importantly, these children 
were transplanted without any conditioning and so the deafness 
could not be attributed to side effects of treatment, thus implicat-
ing metabolic perturbation due to ADA deficiency (45).
Incidence of bilateral sensorineural deafness was also investi-
gated in a larger cohort of ADA-SCID patients receiving BMT – a 
58% incidence was reported in the 12 patients who had undergone 
audiologic assessment in a study by Albuquerque and Gaspar 
(44). This observation was compared against a control group 
of 16 patients, who had received BMT for immunodeficiencies 
specifically affecting and confined to the immune system, and it 
was found that in this control cohort only one child displayed 
bilateral sensorineural hearing loss (6% incidence). No audio-
logic assessments were undertaken prior to transplantation, and 
it is, therefore, not known whether these auditory abnormalities 
existed before treatment. However, deafness is not a complica-
tion typically associated with BMT, and this evidence, therefore, 
supports the hypothesis that auditory abnormalities are not a 
complication from treatment, but are instead likely to be another 
non-immunologic manifestation of ADA deficiency. Although 
there was no visible relationship between severity of deafness 
and dATP levels, affected patients also showed no identifiable 
predisposing factors; therefore, the role of ADA deficiency in 
auditory abnormalities needs to be investigated and further 
defined (44).
evidence for Structural Abnormalities 
Linked to Motor Abnormalities
While there is clear evidence that patients with ADA deficiency are 
susceptible to neurocognitive abnormalities, very little research 
has been done to explore the effect on the brain structurally and 
FiGURe 5 | There is peripheral expression of all four adenosine 
receptor subtypes in the brain, which are found pre, post, and 
non-synaptically (34). A1 receptors are ubiquitously expressed with high 
concentrations particularly found in the cortex, hippocampus, and cerebellum 
(34). Conversely, levels of A2A receptor are generally lower throughout the 
brain but are concentrated predominantly on medium spiny neurons of the 
striatum (34). Furthermore, the A1 receptor subtype is preferentially activated 
by released adenosine, and the A2A receptors are preferentially activated by 
adenosine formed from adenine nucleotides (35). Low levels of A2B and A3 
receptors are found in the brain; these receptors are thought to be involved in 
pathological situations (35, 36).
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sub-structurally. One investigation reported by Nofech-Mozes 
studied three ADA-deficient patients who presented with neu-
rological abnormalities (such as seizures, developmental delay, 
hypotonia) with no other identifiable etiology (for example, 
infection or transplant-related medication toxicity). Cranial 
MRI and computed tomographic (CT) scans showed that these 
patients exhibited volume loss and abnormalities, particularly 
affecting the basal ganglia and thalamus (46). Therefore, it is 
possible that the deficiency of ADA, or the accumulation of 
metabolic substrates, is a possible cause for the neurological 
abnormalities observed in this patient cohort (see Table 1).
Therefore, the evidence presented so far suggests that ADA 
deficiency is somehow associated with the observed neurological 
abnormalities in this metabolic disorder. In fact, neurological 
abnormalities are far more prevalent in ADA-SCID than other 
forms of immunodeficiency, indicating that the underlying 
metabolic disruption caused by ADA deficiency affects the 
CNS, both in function and development. It is not known what 
degree of metabolic detoxification is achieved in the CNS with 
current ADA treatments, nor is it known whether neurological 
abnormalities are present prior to treatment. Evidence provided 
by multiple papers seems to suggest that current treatments 
are not sufficient to prevent the development of and/or correct 
these neurological abnormalities long term (2, 37, 38, 44–46). 
A study investigating CNS outcomes in ADA-deficient patients 
after HSCT found that 6 out of 12 patients, at a mean follow-up 
period of 12 years, showed distinct neurological abnormalities, 
despite displaying complete immune reconstitution (2). Elements 
of all the neurological abnormalities reported above (cognitive 
and behavioral abnormalities, auditory abnormalities, and motor 
abnormalities) are reported in multiple patients within this 
long-term study. Furthermore, this paper presents patients who 
have received transplants both with and without conditioning, 
therefore reiterating previous statements that the neurological 
abnormalities are not treatment-related (2). In addition to the 
display of neurocognitive abnormalities, ADA-deficient patients 
display abnormalities in the brain architecture, such as the ven-
triculomegaly described above (46).
Current research has not, so far, investigated the mechanism 
of pathology. One possibility is that the accumulation of dATP 
causes neurotoxic effects by a similar mechanism elucidated in 
the immune system. To investigate this concept, levels of deoxy-
adenosine and dATP would need to be studied before and after 
various treatments in all ADA-deficient patients, regardless of 
the presence of neurological abnormalities. However, pre- and 
post-measurement of specific parameters, such as cognitive abil-
ity, may be difficult due to the young age of patients at the time of 
diagnosis and/or at treatment (38).
Alternatively, another possible hypothesis is that the high 
concentrations of adenosine could be activating adenosine recep-
tors. Adenosine is identified as a neuromodulator; therefore, it is 
fair to assume that altering levels of neuromodulation will have a 
significant effect within the brain. Adenosine receptors are found 
in particular abundance in the basal ganglia and thalamus, and 
changes in finely tuned synaptic transmission within these brain 
regions may explain some of the neurological abnormalities 
reported in ADA deficiency. Furthermore, there are an array 
of other disease states in which adenosine is pathologically 
implicated, including but not limited to Alzheimer’s disease, 
schizophrenia, epilepsy, and pain (35). Therefore, if adenosine 
is implicated in the pathogenesis of other diseases, it is possible 
that alterations in adenosine metabolism occurring in ADA 
deficiency are affecting the functioning of the CNS, resulting in 
the neurological abnormalities reported in many patients.
Therefore, this highlights the importance of elucidating the 
mechanisms underlying these neurological abnormalities in 
ADA deficiency. This knowledge will aid in the development of 
improved therapies that are capable of correcting and/or pre-
venting neurological abnormalities from occurring in patients. 
It is also important to fully understand the function of ADA 
and the purine salvage pathway in the brain, not only to correct 
the abnormalities seen in ADA deficiency but also to improve 
therapies for other neurological disorders in which adenosine is 
pathologically implicated. This is particularly relevant in the case 
of PNP deficiency that is another PID resulting from defects in 
the purine salvage pathway and, interestingly, a high proportion 
of patients present with neurological abnormalities similar to 
those described in ADA deficiency (47, 48).
ADA iN THe HePATiC SYSTeM
Establishing a model system for disease states is integral to 
fully understanding the underlying molecular mechanisms. 
TABLe 1 | A case report investigating neurological abnormalities in patients with ADA deficiency emphasizes the implication of such abnormalities.
Age of first 
neurological 
abnormality
initial neurological 
presentation
Neurological abnormalities  
(pre- and post- treatment)
Treatment Outcome
4 months Smiling ceased and vocalization 
was reduced, was unable to 
make eye contact
Observed pre-treatment: dilation of  
ventricular system and pericerebral  
fluid spaces
Initial  
supportive 
care  
followed 
by BMT at 
9 months
Little neurologic improvement before BMT
Displayed hypotonia of trunk 
and extremities
Death from respiratory insufficiency and multi-organ 
failure at 11.5 months
Displayed head lag and 
severe rotary nystagmus
3 months Moderate hypotonia with 
head lag
Observed pre-treatment: caudate nuclei, 
basal ganglia, and ventral thalami show 
cystic changes, calcification, and volume  
loss
BMT at 
4 months
Immune reconstitution after treatment
Developed generalized seizures at 5 months
No leukocytes/lymphocytes in CSF
Severe psychomotor retardation at 12 months, with 
hypotonia of all extremities
Non-verbal, poor swallowing coordination and no 
progression in motor or cognitive skills at 6 years
4 months Moderate hypotonia with 
head lag
Observed pre-treatment: prominent 
pericerebral fluid and ventriculomegaly – 
suggestive of extraventribular obstructive 
hydrocephalus
HSCT at 
5 months
12-, 18-, 24-, 36-, and 48-month assessments 
showed severe sensory-neural deafness and 
moderate–severe motor and cognitive psychomotor 
delay
Observed post-treatment: slight resolution 
of pericerebral fluid, but persistence of 
ventriculomegaly
Developed generalized seizures at 2 years
Patients present with neurological manifestations early on in life. This evidence is significant because it identifies structural changes in the brains of these patients, possibly 
caused by ADA deficiency. It also highlights that existing treatments failed to correct and/or prevent progression of the abnormalities. This table was created using data from 
Nofech-Mozes et al. (46).
BMT, bone marrow transplantation; HSCT, hematopoietic stem cell transplantation; CSF, cerebrospinal fluid.
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An ADA-deficient murine model currently exists that replicates 
many of the phenotypes exhibited in patients. However, the 
successes of early attempts to establish a representative mouse 
model were hindered due to adverse effects of ADA deficiency 
on the hepatic system, which were not typically associated with 
patients. This section will look at the effect of ADA deficiency on 
the hepatic system of animals and patients.
evidence in Animals
An ADA-deficient murine model was developed by two inde-
pendent groups who, despite targeting different sites of the gene, 
both successfully developed ADA-deficient mice displaying 
similar phenotypes (21). However, the majority of homozygous 
mice were either stillborn or succumbed within the first 2 days 
postpartum (49). While the exact time point was unclear, it was 
estimated that a narrow window of death existed around the time 
of parturition (49, 50). Histological analysis showed normal lym-
phoid tissues in the majority of ADA-deficient mice, but changes 
in liver, small intestine, and lung were revealed (49, 50). The liver 
was particularly affected – hepatocytes appeared morphologically 
altered, and the affected number increased with gestational age, 
hence indicating that the metabolic disorder underlying ADA 
deficiency caused pathology in the murine liver (50). Further 
investigation revealed marked changes in the levels of adenosine 
and deoxyadenosine in the liver, which were barely detectable 
in control and heterozygous mice but were found at extremely 
elevated levels in ADA-deficient mice (49). Additionally, levels of 
dAXP were higher in deficient mice and there was a reduction in 
activity levels of SAH hydrolase (49). In summary, ADA-deficient 
mice exhibited severe hepatocyte impairment and degeneration 
that proved perinatally lethal.
evidence in Patients
It is evident that ADA plays an integral role in the liver during 
fetal development of the murine model. However, the effects in 
ADA-deficient patients are not perinatally lethal and hepatic dys-
function has rarely been reported. For example, in one particular 
report, a neonatal ADA-SCID patient exhibited hyperbilirubine-
mia and hepatitis; but both pathologies were successfully resolved 
following treatment with ERT (51). Additional clinical findings 
include histological abnormalities and liver stiffness alongside 
fatty liver and/or hepatomegaly, with abnormalities appearing to 
resolve alongside ERT (52). However, other supportive clinical 
data are hard to find.
In conclusion, there is evidence for hepatic abnormalities in 
the murine model and, to a much lesser extent, ADA-deficient 
patients. ADA-deficient mice exhibited severe hepatocyte impair-
ment and degeneration that proved to be perinatally lethal. 
The severe pathology exhibited suggests that the mother was 
incapable of detoxifying the fetal metabolic load caused by ADA 
deficiency: indeed, accumulation of metabolic substrates has 
been demonstrated experimentally (49, 50). One hypothesis is 
that adenosine kinase (ADK), suggested to be the main pathway 
of deoxyadenosine phosphorylation in mice, is abundant in the 
TABLe 2 | Pulmonary abnormalities observed in ADA-deficient mice 
include pulmonary inflammation and airway remodeling, shown by 
various pathological changes (53, 54).
Tissue damage and airway 
remodeling
Pulmonary inflammation
↑ Size of alveolar spaces
↑ Thickness of pulmonary blood vessel 
smooth muscle
↑ Number of inflammatory cells:
• Eosinophil infiltration
• Large and foamy macrophages
Alveolar macrophages engulfing 
eosinophils in BALF
Hypertrophy of bronchial epithelium
↑ Mucus production Accumulation of activated alveolar 
macrophages and eosinophilsOcclusion of airways with cellular debris
BALF, bronchoalveolar lavage fluid.
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liver and, therefore, dATP accumulation is likely and may cause 
the hepatic abnormalities (50). The accumulation of adenosine 
shows a 30- to 100-fold increase and could also be the cause of 
hepatic damage via adenosine receptor activation (49). Akin 
to the immune system, deoxyadenosine mediates inhibition of 
SAH hydrolase and, therefore, the accumulation caused by ADA 
deficiency may be responsible for reduced activity.
Therefore, it is possible that accumulation of a combination 
of metabolic substrates causes perinatally lethal hepatic damage 
in ADA-deficient mice. While this lethality is not mimicked in 
patients, ADA is still ubiquitously expressed and hepatic abnor-
malities should not be overlooked as a possible non-immunolog-
ical manifestation. In fact, it has been stated that elevated serum 
transaminase levels may be seen in patients with ADA deficiency: 
this is indicative of liver damage and often etiology is unknown 
(49). Therefore, although patient data are limited, there is suffi-
cient murine evidence to suggest that ADA deficiency can largely 
impact upon the liver and, therefore, hepatic abnormalities may 
possibly occur in patients due to metabolic disruption and, thus, 
warrants further investigation.
ADA iN THe PULMONARY SYSTeM
As previously mentioned, homozygous ADA knockout mice of 
the initial murine model died either before or shortly after birth, 
seemingly due to consequences of metabolic disorder. In order 
to overcome the perinatal lethality caused by ADA deficiency, 
genetically engineered mice were developed in which ADA activ-
ity was restored to the trophoblast cells only (21, 53). Therefore, 
mice no longer succumbed perinatally and postnatally exhibited 
multiple phenotypes of ADA deficiency, including pulmonary 
insufficiency (53).
evidence in Animals
These newly modified ADA-deficient mice survived past 
birth, but instead died from severe respiratory distress: initial 
symptoms of tachypnea were observed around day 12 postpar-
tum and progressed until days 19–25, when mice succumbed 
(53). Upon further investigation, ADA-deficient mice exhibited 
severe pulmonary inflammation; the airways also appeared 
to have undergone remodeling and were hyperresponsive 
(see Table 2) (21, 53).
In order to ascertain whether the observed phenotype was 
related to the deficiency of ADA, the effect of ERT on the lung 
abnormalities was investigated (53, 54). PEG-ADA was admin-
istered to the ADA-deficient mice at day 18, by which point 
the pulmonary phenotype was fully established (53). An initial 
decrease in eosinophils was monitored, and a further decrease in 
alveolar macrophages occurred after 2 weeks of ERT. This study 
also observed a reduction in mucus production in the enzyme-
treated mice, although an improvement in alveolar enlargement 
was not observed. However, since this observation on alveolar 
enlargement was made after 72  h, it could be possible that an 
improvement might be seen after a longer time period. This 
study, therefore, demonstrates that particular elements of both 
pulmonary inflammation and airway remodeling appear to 
be reversed by ERT (53). It was also reported that treated mice 
demonstrated significantly lower levels of respiratory distress 
and remained alive while maintained on therapy. This evidence 
indicates that the observed pulmonary abnormalities are likely 
to be caused by the deficiency of ADA. Moreover, a decrease in 
both adenosine and 2′-deoxyadenosine levels were measured in 
PEG-ADA treated mice (53).
A more recent paper describes development of pulmonary 
fibrosis in ADA-deficient mice (55). ADA-deficient mice were 
treated with varying concentrations of PEG-ADA, and the effect 
of changing endogenous adenosine concentrations in the lungs 
was monitored. High adenosine concentrations in the lung 
(achieved by low dosage ERT) resulted in pulmonary inflamma-
tion and airway remodeling (as seen in previous reports), but also 
resulted in the expression of profibrotic molecules and collagen 
deposition – these are characteristic indicators of pulmonary 
fibrosis. In fact, it was demonstrated that reducing adenosine 
levels after the initial onset of pulmonary fibrosis was sufficient 
to resolve the established fibrosis (55).
Another pulmonary phenotype observed in ADA-deficient 
mice is pulmonary alveolar proteinosis (PAP), a rare lung disor-
der that can result in progressive respiratory failure. This has been 
identified in mice, in addition to the pulmonary inflammation 
and airway restructuring seen previously (56).
Therefore, it is evident that ADA and its role in metabolism 
has significant consequences for the murine respiratory system 
in a multitude of ways.
evidence in Patients
Patients with ADA deficiency present with severe lung abnor-
malities; however, this is not unique to ADA-SCID, and lung 
abnormalities are present in other variants of SCID (57). 
Nevertheless, there is substantial evidence that the development 
of lung abnormalities in ADA deficiency is not infection related 
and, rather, likely to be derived from metabolic insufficiency 
(57). This study also demonstrated that while patients with 
two different forms of SCID (ADA and X-linked) both exhibit 
similar radiological and respiratory findings, positive microbi-
ology from respiratory cultures is significantly less frequent in 
ADA-deficient patients. Therefore, it is highly likely that patients 
with ADA deficiency develop non-infective lung abnormalities. 
Histological analysis of these non-infective lung lesions in symp-
tomatic patients has shown that the abnormalities are highly 
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suggestive of PAP (57, 58). Therefore, ADA-deficient patients 
exhibit similar pulmonary phenotypes to those observed in the 
murine model (58). The incidence of ADA-deficient patients 
with PAP was reported to be 43.8% in this Grunebaum study, 
where 7/16 patients showed characteristic lung pathology 
indicative of PAP that was not observed in patients with other 
forms of SCID (0/22). Further comparisons of ADA patients 
showed that there was no significant difference in clinical and 
immunological characteristics between those diagnosed with 
PAP and not diagnosed with PAP and, therefore, the pathology 
is likely to be a non-immunological abnormality resulting from 
ADA deficiency. Furthermore, it was found that treatment for 
ADA deficiency (including PEG-ADA or HSCT) appeared to 
correct the pulmonary complications: all patients (but one) 
showed rapid resolution of PAP (58).
A recently emerging technique (impulse oscillometry) was 
employed to measure lung function via a method alternative 
to spirometry, and this also highlighted a high incidence of 
airway dysfunction in ADA-SCID patients (59). Furthermore, 
use of this methodology within this study demonstrated that 
peripheral airway dysfunction is still present in a significant 
fraction of ADA-SCID patients post-treatment (specifically 
ERT and GT). Not only does this add weight to the hypothesis 
that perturbations in adenosine metabolism are linked to the 
development of pulmonary abnormalities in ADA deficiency, 
but it also suggests that current therapies may not be sufficiently 
controlling and/or preventing pulmonary abnormalities in 
ADA deficiency.
ADA iN THe SKeLeTAL SYSTeM
From the cumulative evidence so far, it is clear that ADA defi-
ciency has a multi-organ system pathology. Bone defects are 
radiologically detectable in ~50% of patients with early-onset 
ADA deficiency (60). However, bone defects are also observed 
in other immunodeficiencies and, therefore, it is unclear whether 
the bone abnormalities exhibited in ADA deficiency are a result of 
the perturbations in purinergic metabolism or secondary to the 
immunodeficiency (60).
evidence in Animals
Adenosine deaminase-deficient mice exhibit bony abnormali-
ties, including rib cage curvature and enlarged costochondral 
junctions (21). Similar bony phenotypes are seen between ADA-
deficient mice and Rag2γc−/− mice (another immunodeficiency) 
(60). However, this Sauer led study showed that in fact some 
bone abnormalities, such as low bone mass, were observed only 
in ADA-deficient mice, therefore implying that at least some of 
the displayed bony phenotype must be a direct consequence of 
ADA deficiency. Investigating the ADA-deficient bone pheno-
type more extensively showed reduced bone formation resulting 
from decreased osteoclastogenesis and impaired osteoblast (OBs) 
function. Additionally, this study also showed the bone mar-
row microenvironment to be defective in its ability to support 
hematopoiesis in ADA-deficient mice. Furthermore, neonatal 
treatment with ERT, HSCT, and GT in these mice can lead to 
correction of the altered bone phenotype (60).
evidence in Patients
It is common for patients with ADA deficiency to display costo-
chondral abnormalities and skeletal dysplasia (60). An autopsy 
report of ADA-SCID patients found short growth plates, within 
which only a few proliferating and some hypertrophic chon-
drocytes were found (61). This autopsy also revealed necrotic 
chondrocytes and high levels of cellular debris in these patients. 
However, other immunodeficiencies also display bone abnor-
malities, and bony pathology that is supposedly characteristic 
to ADA-SCID has been found in patients with normal ADA 
activity, albeit to a lesser extent (60, 62). Therefore, it is unknown 
whether these bony defects are caused by the disrupted purine 
metabolism or the underlying immunodeficiency (10, 60). 
However, since there seems to be a bony phenotype found more 
specifically among ADA deficiency, it can be hypothesized that 
the bony abnormalities may also be formed independently of the 
immunodeficiency (60).
Osteoblasts and osteoclasts (OCs) are two important cell types 
found within the bone, responsible for formation and resorption 
of bone, respectively, and therefore interaction between the two 
is critical for maintenance of bone homeostasis (60). RANKL and 
its decoy receptor OPG are responsible for mediating cross-talk 
between OBs and OCs, and the RANKL:OPG ratio regulates the 
formation and activity of OCs. Therefore, RANKL and OPG play 
important roles within the bone environment. OBs are a source of 
RANKL, but RANKL can also be produced by activated T and B 
cells. Similarly, B cells within the bone marrow are a major source 
of bone marrow OPG. Therefore, since ADA deficiency is char-
acterized by T- and B-cell lymphopenia, the consequent effect of 
this on the RANKL/OPG axis implicates an immune-dependent 
process that can lead to bony abnormalities. OBs and OCs both 
express adenosine receptors, and therefore abnormal adenosine 
signaling as a result of increased adenosine concentrations may 
also play an important role in modulating their activity and be a 
causal factor in the development of bone abnormalities in ADA 
deficiency (60).
An additional hypothesis suggested is that the OB defect may 
play another contributory role in the bony abnormalities observed 
in both ADA-deficient patients and the murine model (60). 
Wild-type OBs have high ADA enzymatic activity, but there is a 
threefold reduction in activity in mesenchymal progenitor cells, 
from which OBs originate and suggests that OB differentiation 
must involve upregulation of ADA expression. Hence, since OBs 
become increasingly dependent on ADA during proliferation and 
differentiation, ADA deficiency could potentially have a severe 
impact on the viability and function of OBs. This hypothesis is 
explored in  vitro, whereby lentiviral vector transduction with 
functional ADA gene is sufficient to correct the growth defects 
seen in ADA-deficient OBs (60).
Therefore, bony abnormalities do exist in ADA deficiency, and 
these appear, in part, to be a non-immunological manifestation 
and not entirely secondary to the immunodeficiency. This ought 
to be taken into consideration in the treatment of ADA deficiency; 
all three treatments of ERT, BMT, and GT achieve near-complete 
corrections of bone abnormalities in mice, yet this efficiency is 
not entirely replicated in patients. It has been suggested that ERT 
may be less efficient in patients, since mice receive a high dosage 
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of PEG-ADA at an earlier time point than patients typically 
receive treatment (60).
Therefore, a full understanding of the immune-dependent 
and immune-independent pathogenesis might lead to improved 
therapy and correction of bony abnormalities.
ADA iN THe ReNAL SYSTeM
While reports of renal abnormalities in ADA deficiency are 
not in abundance, there is still sufficient evidence to link ADA 
deficiency with kidney dysfunction. Adenosine is known to play 
an integral and diverse role in kidney function and, therefore, this 
system may be susceptible to alterations in purine metabolism 
caused by ADA deficiency (63).
evidence in Mice
Renal abnormalities have been noted in ADA-deficient mice, 
although in comparison to other organ systems, this appears 
not to have been fully investigated. Early reports on the ADA-
deficient mouse model noted abnormalities in the kidneys, 
including a change in appearance. There was also a large increase 
in number of red blood cells present in both the glomeruli and 
convoluted tubules (21). Similar observations were noted in 
a paper investigating chronic kidney disease (64). This group 
employed the ADA mouse model to demonstrate renal dysfunc-
tion and fibrosis: mice receiving a low dose regimen of ERT, thus 
modeling ADA deficiency, exhibited significant vascular damage 
and fibrosis in the glomeruli and interstitial tissues. These renal 
abnormalities appeared to be prevented when deficient mice were 
maintained on a high dosage PEG-ADA regimen.
evidence in Patients
Initial observations from an autopsy report of ADA patients 
revealed renal abnormalities including: mesangial sclerosis in 
seven cases, with two showing global sclerosis in 5–10% of glo-
meruli (61). Increased mesangial matrix was additionally seen in 
three cases. A recent publication provides further evidence link-
ing ADA deficiency with renal dysfunction: hemolytic uremic 
syndrome (HUS) is a common cause of renal failure in young 
children, and this manifestation is reported in a cohort of ADA-
SCID patients (9). Coincidentally, ERT led to successful stabiliza-
tion of renal function in two of these patients in this study.
Adenosine deaminase is ubiquitously expressed, and despite 
the scarcity of evidence about renal abnormalities caused by 
ADA deficiency, it would be an oversight to assume the underly-
ing metabolic disturbance caused by ADA deficiency does not 
affect renal function. Therefore, further research is required to 
investigate this concept.
Similar to other non-immunologic manifestations, the under-
lying mechanism of renal pathology is not known. However, 
research is being focused on the role of adenosine signaling on 
kidney function. Dai et al. investigated a link between A2B adeno-
sine receptor activation (caused by increased renal adenosine) and 
renal dysfunction, not only in the ADA-deficient mice but also 
in two other mouse models. Specifically, this group identifies the 
induction of IL-6 downstream of A2B adenosine receptor activa-
tion as a contributing candidate for the observed renal fibrosis, 
although it has also been demonstrated that mice deficient in IL-6 
are not protected from developing renal fibrosis (64, 65).
However, it is possible that adenosine signaling may play a 
dual role within the renal system: it seems that under conditions 
where adenosine concentrations are persistently elevated, as 
in ADA deficiency, A2B receptor signaling can promote renal 
fibrosis. On the other hand, it does also appear that short-term 
activation of the A2A and A2B adenosine receptors can decrease 
inflammation and reduce fibrosis (65). ADA-deficient mice are 
shown to display increased levels of A2B receptor expression, and 
perhaps this avenue warrants further investigation to allow us to 
distinguish between the protective and harmful role of adenosine 
signaling (64).
Similar to the case in mice, adenosine-mediated receptor 
activation has again been implicated in patients – downstream 
actions in the renal system include constriction of afferent renal 
arterioles and reduction in glomerular filtration via A1 adenosine 
receptor activation (9). Although this would not explain the diag-
nosis of HUS, it may provide an explanation for the severe renal 
failure exhibited by ADA-deficient patients, and the subsequently 
poor clinical response (9).
ADA AND SKiN TUMORS
Dermatofibrosarcoma protuberans (DFSP) is a mesenchymal 
tumor of the skin and its incidence in the general population is 4.2 
per million. One study describes the occurrence of this rare skin 
tumor in 12 unselected patients with ADA deficiency (66). The 
frequency of this observation suggests that ADA patients have a 
susceptibility to this particular tumor. The mechanism is unclear, 
but, given that some tumors developed after successful HSCT 
or ERT, a lack of tumor surveillance is unlikely, although a very 
specific defect cannot be excluded. It was also suggested that high 
levels of tissue adenosine could predispose to a more fibrogenic 
dermal environment that, when coupled to an increased rate of 
single-strand DNA breaks caused by elevated deoxyadenosine, 
could lead a more tumorigenic predisposition in the skin of ADA-
deficient individuals. Again, this requires further monitoring and 
investigation.
CONCLUSiON
Adenosine deaminase deficiency is a SCID that manifests itself 
in multiple organ systems. Treatment is essential and life-saving, 
yet improvements still need to be made to ensure the systemic 
multi-organ pathology is corrected. Since ADA deficiency is a 
metabolic disorder, substrate accumulation is assumed to under-
lie the pathogenesis. However, to a large extent, it is still relatively 
unknown by which mechanism this occurs. Having elucidated the 
mechanisms within the immune system, deoxyadenosine may act 
in a similarly toxic manner in other organ systems and may be 
additionally responsible for the non-immunological manifesta-
tions. Alternatively, the impact of adenosine and its downstream 
signaling pathway following receptor activation should also be 
considered.
Therefore, having clearly laid out the evidence for ADA defi-
ciency as a multi-organ system disease, it is important to further 
investigate the mechanisms underlying the different organ 
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manifestations in order to improve existing treatments and allow 
a more complete correction.
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